Shares of health-care companies rose as an increased appetite for risk helped the biotech sub sector.
Shares of Mylan rallied after the Food and Drug Administration approved commercialization of a generic version of multiple-sclerosis drug Copaxone. The development weighed on shares of Copaxone maker Teva Pharmaceutical.
Continue Reading Below
Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
October 04, 2017 16:56 ET (20:56 GMT)